A retrospective study comparing a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen (BuEM) versus carmustine, etoposide, cytarabine and melphalan (BEAM) for autologous hematopoietic cell transplant in advanced Hodgkin and non-Hodgkin lymphomas.

Trial Profile

A retrospective study comparing a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen (BuEM) versus carmustine, etoposide, cytarabine and melphalan (BEAM) for autologous hematopoietic cell transplant in advanced Hodgkin and non-Hodgkin lymphomas.

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Busulfan (Primary) ; Etoposide (Primary) ; Melphalan (Primary) ; Carmustine; Cytarabine
  • Indications Haematological malignancies; Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top